Last reviewed · How we verify
NCT06923306: VIVID 2
Virtual Reality Exposure for Vaginismus: A Replicated Single-Case Design
NA trial testing Virtual reality exposure in Vaginismus in 20 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | University of British Columbia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 April 2025 |
| Primary completion | 30 November 2026 |
| Estimated completion | 30 January 2027 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Virtual reality exposure
Conditions studied
- Vaginismus — all drugs for Vaginismus →
Sponsor
University of British Columbia
Who can join
19 and older, female only, with Vaginismus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Vaginismus is a sexual dysfunction characterized by involuntary tightening of the pelvic floor muscles, preventing vaginal intercourse. It is defined by an intense fear of vaginal penetration, leading to persistent difficulties with vaginal intercourse and gynaecological exams. Psychological factors play a significant role in vaginismus. If the pelvic floor muscle tightening represents a defensive reflex, then treatment using a gradual exposure to feared stimuli using virtual reality may lead to an extinction of the phobic response, and to amelioration of vaginismus. If effective, the use of virtual reality technology can directly improve clinical care offered to those suffering from vaginismus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06923306
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Virtual reality exposure
Trials testing the same drug.
- NCT06104176 — Effectiveness of Virtual Reality Therapy in Alcohol Use Disorder Study · NA · recruiting
- NCT06446518 — Assessing Virtual Reality for Perioperative Anxiolysis in Adolescents Undergoing MIRPE Surgery · NA · completed
- NCT04419077 — Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act · NA · completed
Other recruiting trials for Vaginismus
Currently open trials in the same condition.
- NCT06397885 — Prospective on Market Patient-reported Outcomes for Milli · active not recruiting
Other University of British Columbia trials
Trials by the same sponsor.
- NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
- NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
- NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
- NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
- NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06923306 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06923306.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing